Abstract
Purpose :
To investigate the 6-month treatment effect of 0.01% atropine on myopic changes in children with different initial predicted myopia progression rates (PMPR) measured by global flash multifocal ERG (mfERG)
Methods :
24 children aged 8 to 9 years were randomly assigned to the treatment group (T, n=12) of 0.01% atropine and the control group (C, n=12) of artificial tears. Cycloplegic objective refraction (SER), axial length (AL) measurement and mfERG were performed at baseline and after 6 months of daily treatment. Central mfERG response from the tested eye of each subject at baseline was analyzed to determine the PMPR according to our previous study (DOI:10.1167/iovs.16-21279). The changes in refractive errors and axial length of the tested eye were calculated and compared within group and between groups by Mann-Whitney U test.
Results :
After 6-month atropine treatment, group T showed a mean change of -0.12D in SER and 0.15mm in AL, while group C had a change of -0.44D and 0.21mm. There was a significant difference in SER between groups (p=0.03). There were 4 and 8 subjects with slow and fast PMPR respectively in group T; while 3 and 9 subjects with slow and fast PMPR respectively in group C. Those with slow PMPR in group T and C showed similar mean change of myopia progression (T: DSER=-0.31D; DAL=0.18mm; C: DSER=-0.33D; DAL=0.21mm). However, those with fast PMPR in group T showed a significant less myopia change as compared those in group C (T: DSER=-0.06D; DAL=0.18mm; C: DSER=-0.47D; DAL=0.22mm, p=0.02 for SER).
Conclusions :
The 6-month 0.01% atropine treatment was shown to be effective in reducing myopia progression for the children who have fast PMPR measured by mfERG, but not for those who had slow predicted rate.
This is a 2020 ARVO Annual Meeting abstract.